Skip to main content
Scientific Reports logoLink to Scientific Reports
. 2022 Feb 28;12:3285. doi: 10.1038/s41598-022-07084-9

Nosocomial infections in female compared with male patients with decompensated liver cirrhosis

Marie Griemsmann 1, Tammo L Tergast 1, Nicolas Simon 2, Abdul-Rahman Kabbani 1, Michael P Manns 1,3,4, Heiner Wedemeyer 1, Markus Cornberg 1,3,4, Benjamin Maasoumy 1,3,4,✉
PMCID: PMC8885665  PMID: 35228572

Abstract

There are considerable differences between males and females regarding the etiology, progression and outcome of liver diseases. Infections are a frequent and severe complication in these patients. This study aimed to examine sex specific differences in the incidence and clinical course of nosocomial infections in patients with decompensated liver cirrhosis. A number of 556 consecutive hospitalized patients with decompensated liver cirrhosis and ascites were analyzed. The patients were followed up for the incidence of nosocomial infections, acute kidney injury (AKI), acute-on-chronic liver failure (ACLF) as well as liver transplantation and death (LTx-free survival). A number of 285 patients (111 women and 174 men) developed a nosocomial infection. Incidence was numerically lower in men (P = 0.076). While the frequency of a nosocomial spontaneous bacterial peritonitis was similar between males and females, the incidence of a nosocomial urinary tract infection was significantly higher in women (P < 0.001). No sex specific differences were documented regarding the outcome of an infection as indicated by a similar incidence of, AKI, ACLF as well as LTx-free survival. There seem to be no major differences in the incidence and outcome of nosocomial infections between male and female patients.

Subject terms: Liver, Gastroenterology, Hepatology, Liver diseases, Liver cirrhosis

Introduction

Over the recent years sex specific differences gain an increasing attention in medical research. Relevant differences include pharmacokinetic and pharmacodynamics of drugs, prevalence as well as natural history of several diseases1–4. This certainly also affects the field of hepatology. E.g. women are more likely to suffer from autoimmune hepatitis and primary biliary cholangitis5,6 whereas men develop more frequently primary sclerosing cholangitis7. Further, the progression of liver disease to fibrosis and cirrhosis differs. The toxic effect of alcohol is greater in females than in males, which leads to faster development of fibrosis in women with alcohol-related liver disease8–10. However, this progress is opposite in other etiologies of cirrhosis such as hepatitis B and C11, hemochromatosis and primary biliary cholangitis9,12. These differences were partly explained by diverse levels of sex hormones. Of note, the advantage of female sex in patients with hepatitis C diminishes after the menopause9,13.

Recently, several studies suggested sex specific differences in end stage liver disease. Female patients with decompensated liver cirrhosis on the waiting list for liver transplantation were more likely to die and less likely to be transplanted than male patients in some studies14,15. The impact of creatinine in MELD score has been suggested as a possible explanation16,17. However, this remains controversial. Of note, Mariante-Neto et al. did not observe any differences in survival and chance for transplant between sexes in a similar study design18 and the study by Umemura et al. even documented a better survival for female patients19.

One of the most common and severe complication in end stage liver disease are infections, particularly if acquired during hospitalization. The natural history of liver cirrhosis is significantly altered by an infection20. Mortality is four times increased21. Even after resolution of infection the survival remains impaired20,22. Moreover, infections trigger further cirrhosis-associated complications such as hepatic encephalopathy23, acute-on-chronic liver failure (ACLF)24 and acute kidney injury (AKI)25. Fast diagnosis and adequate treatment of infections as well as sufficient measures for prophylaxis are absolutely crucial, in particular in those with decompensated liver disease26. Therefore, it is of particular importance to know about the most common sites of infection and specific risk factors. Of note, the influence of sex on the incidence and clinical outcome of as well as risk factors for nosocomial infections in patients with decompensated liver cirrhosis has rarely been investigated in detail, so far.

This study aimed to study sex specific differences in incidence and the clinical course of as well as risk factors for nosocomial infections in a large real-world cohort of patients with decompensated liver cirrhosis and ascites.

Patients and methods

Patient cohort

A number of 1314 consecutive hospitalized patients who underwent a paracentesis from January 2012 until April 2018 at Hannover Medical School were considered for the study. In a first step, patients were selected automatically by the Enterprise Clinical Research Data Warehouse to avoid selection bias. Afterwards, the medical records of the patients were checked manually for inclusion and exclusion criteria leaving 556 individuals for the final analysis. Exclusion criteria included insufficient evidence of cirrhosis, malignant tumor disease other than hepatocellular carcinoma within the MILAN criteria, secondary intraabdominal infection, no sufficient follow up of nosocomial infection, HIV infection, congenital immune dysfunction, history of organ transplantation and no sufficient informed consent (Suppl. Fig. 1).

Data collection

Clinical information like presence of infection, age, medication, AKI, ACLF and death was collected manually from the patients’ files. Laboratory values at time of admission and time of infection were extracted automatically by the Enterprise Clinical Research Data Warehouse. Diagnosis of liver cirrhosis was confirmed by ultrasound, elastography, liver histology, biochemical results and/or a combination of the above. Definition of infection was based on the judgement of the treating physician and/or clinical symptoms in combination with the following criteria:

  • Spontaneous bacterial peritonitis (SBP): ≥ 500 nucleus containing cells/mm3 ascites fluid

  • Urinary tract infection (UTI): leukocyturia and/or positive urine cultures and/or significant germination number as well as respective clinical signs of infection

  • Pneumonia: evidence of pulmonary infiltrates in X-ray and respective clinical signs of infection

  • Blood stream infection: clinical signs of infection and positive blood cultures

AKI and ACLF were defined according to the guidelines of “The European Association for the Study of the Liver” (EASL)24,27–30.

Study design

Sex specific differences in the incidence of nosocomial infections

The patients were followed up 28 days from hospital admission for nosocomial infections. A competing risk analysis was performed handling death and LTx as competing events. As potential risk factors for any nosocomial infection sex, diabetes, age as well as MELD score, and platelets (both indicating the severity of liver disease) were included. In the univariate and multivariate competing risk analysis for incidence of nosocomial SBP the following parameters were considered for the model: presence of peritoneal catheter, antibiotic prophylaxis with norfloxacin and prior SBP. When analyzing potential risk factors for nosocomial UTI presence of a urinary catheter was added to the multivariate model. In a second step the cohort was divided into the two subgroups (female and male patients) to evaluate if specific risk factors for the development of a nosocomial infection are sex-specific.

Sex specific differences in the outcome of nosocomial infection

LTx-free survival

Primary end point was liver transplantation or death (LTx-free survival) within 28 days after the onset of any nosocomial infection, SBP and UTI, respectively. Parameters considered for the univariate and multivariate Cox-Regression model were:

  • Patients characteristics: sex, age, diabetes and esophageal varices

  • Medication: β-Blocker and PPI intake

  • Laboratory values: MELD score, albumin, CRP, leukocytes, sodium and platelets. Protein in ascites and nucleus containing cells in ascites were additionally included in the analysis for LTx-free survival after SBP.

Incidence of AKI

A competing risk model with LTx and death as competing risk was chosen. Follow-up was 28-days after the onset of nosocomial infection. All patients with dialysis or occurrence of AKI before the onset of nosocomial infection were excluded from this analysis. The multivariate competing risk model was adjusted to the parameters sex, MELD score, CRP and platelets. All laboratory values were assessed at the onset of the infection.

Incidence of ACLF

A competing risk analysis with death and LTx as competing risk was performed. Follow-up was 28-days after the onset of nosocomial infection. The multivariate competing risk model was adjusted to the parameters sex, MELD score, CRP and platelets.

Statistics

All analyses were performed with IBM SPSS Statistics 26. Continuous variables were expressed as means and categorical variables as percentages. T-test was used for continuous variables and chi-square-test for categorical variables.

To asses LTx-free survival univariate and multivariate Cox-regression (backward conditional) were applied. All parameters with P ≤ 0.05 and the investigated factor sex were included in multivariate analysis.

Incidence of nosocomial infection, incidence of AKI and incidence of ACLF were analyzed by competing risk analysis. Multivariate competing risk analyses were performed in R Studio 3.5.2 with ‘crrstep-package’31–33. Backward direction was chosen and AIC criterion selected. Transformation into p-values and Hazard Ratios was done by using the function crrstep.output34. Cumulative incidences were executed with ‘cmprsk’ package35.

Ethics

The study was approved by the local ethic committee of Hannover Medical School (Nr. 7935_BO_K_2018) and was performed according to the Declaration of Helsinki. All included patients provided sufficient written informed consent for the scientific use of their clinical data at hospital admission.

Results

Study cohort

Overall, 203 (36.5%) women and 353 (63.5%) men were included in the study cohort. The mean age of the individuals was 57 years. There were some differences in the baseline characteristics between female and male patients: Alcohol-related liver disease was more common in men (P = 0.002) whereas cholestatic (P = 0.011) etiology was more frequent in women. Esophageal varices were more often present in male than in female patients (P = 0.003). Further, the MELD score (P = 0.016) and the Serum-Creatinine (P = 0.003) were higher in men. Moreover, men had a lower platelet count (P = 0.029). The detailed baseline characteristics are displayed in Table 1.

Table 1.

Baseline characteristics.

Variable All patients Female Male P-value
(n = 203, 36.5%) (n = 353, 63.5%)
Age (years) 56.8 (11.1) 56.3 (11.4) 57.1 (11.0) 0.448
Etiology of liver cirrhosis
Alcohol-related 52% (n = 291) 44% (n = 89) 57% (n = 202) 0.002
Cryptogenic 11% (n = 61) 13% (n = 27) 10% (n = 34) 0.183
Viral 18% (n = 102) 17.2% (n = 35) 19% (n = 67) 0.61
NASH 7% (n = 38) 7% (n = 15) 7% (n = 23) 0.694
Cholestatic 8% (n = 42) 11% (n = 23) 5% (n = 19) 0.011
Other 14% (n = 79) 16% (n = 33) 13% (n = 46) 0.294
Mixed 10% (n = 55) 9% (n = 19) 10% (n = 36) 0.75
Cause of hospitalization
Ascites 65% (n = 361) 65% (n = 131) 65% (n = 230) 0.882
TIPS-Evaluation 20% (n = 110) 16% (n = 33) 22% (n = 77) 0.113
LTx-Evaluation 14%(n = 78) 14% (n = 29) 14% (n = 49) 0.895
HE 6% (n = 32) 5% (n = 10) 6% (n = 22) 0.524
HRS 3% (n = 17) 1% (n = 3) 4% (n = 14) 0.101
Worsening of general condition 5% (n = 26) 4% (n = 9) 5% (n = 17) 0.837
Infection 2% (n = 10) 2% (n = 4) 2% (n = 6) 0.817
ACLF 2% (n = 10) 2% (n = 4) 2% (n = 6) 0.817
Other cause 29%(n = 161) 34% (n = 69) 26% (n = 92) 0.047
PPI intake 81% (n = 445) 77% (n = 154) 83% (n = 291) 0.078
Β-blockers 38% (n = 212) 34% (n = 69) 41% (n = 143) 0.136
Esophageal varices 76% (n = 422) 69% (n = 140) 80% (n = 282) 0.003
Diabetes 24% (n = 135) 23% (n = 47) 25% (n = 88) 0.638
MELD score 18 (7.0) 17 (6.6) 19 (7.2) 0.016
Albumin (g/l) 27.1 (5.9) 26.6 (5.4) 27.4 (6.2) 0.273
Bilirubin (µmol/l) 91.9 (135.4) 86.6 (130.6) 94.9 (138.2) 0.488
CRP (mg/l) 30.4 (34.7) 30.1 (38.3) 30.5 (32.5) 0.903
INR (Ratio) 1.53 (0.46) 1.49 (0.37) 1.55 (0.50) 0.209
Creatinine (µmol/l) 130.6 (89.2) 115.6 (70.5) 139.2 (97.3) 0.003
Leukocytes (103/µl) 8.8 (6.1) 9.3 (5.9) 8.6 (6.2) 0.164
Platelets (103/µl) 147.6 (102.7) 160 (119.7) 140 (90.8) 0.029
Sodium (mmol/l) 134 (5.4) 134 (5.5) 134 (5.3) 0.863
Antibiotic intake within 12 weeks before admission 33% (n = 180) 32% (n = 64) 33% (n = 116) 0.818

All continues variables are displayed as mean with standard deviation. Categorical variables are displayed as proportions.

Laboratory values were assessed at time of admission.

In some patients several causes of hospitalization were present.

Significant values are in bold.

MELD model of end stage liver disease, HE hepatic encephalopathy, HRS hepatorenal syndrome, TIPS transjugular intrahepatic portosystemic shunt, LTx liver transplantation, ACLF acute on chronic liver failure, PPI proton pump inhibitors, CRP C-reactive protein, INR international normalized Ratio.

Incidence and clinical course of a nosocomial infection in male vs. female patients

Overall, 258 patients (111 women and 174 men) developed a nosocomial infection. The cumulative incidence function indicated no major difference in the incidence of nosocomial infections between male and female patients (P = 0.283) (Fig. 1). Of note, after adjusting for other risk factors in the multivariate competing risk model, male sex was linked to a numerical lower hazard (HR: 0.81; P = 0.076). However, a statistically significant link to the incidence of nosocomial infections was only found for the MELD score (HR: 1.05; P < 0.001) (Table 2). Noteworthy, this was also consistent in both subgroups (female and male patients) and no sex-specific risk factors were detected.

Figure 1.

Figure 1

Incidence of nosocomial infection. Death and LTx were treated as competing risk. LTx: liver transplantation.

Table 2.

Multivariate competing risk analysis of incidence of nosocomial infection.

Variable (all patients) P-Value Hazard ratio (CI)
Male sex 0.076 0.8073 (0.6381, 1.0214)
MELD score  < 0.001 1.0515 (1.0333, 1.0700)
Platelets 0.12 1.0009 (0.9998, 1.0021)

Included parameters: sex, MELD score, diabetes, age and platelets.

MELD model of end stage liver disease, CI Confidence interval.

Outcome measures of nosocomial infection were AKI, ACLF and LTx-free survival. There was no difference between male and female patients in terms of the incidence of AKI, ACLF (data not shown) and LTx-free survival in the multivariate analysis (Table 5).

Table 5.

Uni- and multivariate Cox-regression of LTx-free survival after the onset of nosocomial infection.

Variable Univariate Multivariate
P-value Hazard ratio (CI) P-value Hazard ratio (CI)
Sex (male) 0.724 0.906 (0.522; 1.570) 0.614
Age 0.420 0.991 (0.968; 1.014)
Diabetes 0.763 0.908 (0.486; 1.698)
Esophageal varices 0.705 0.891 (0.490; 1.620)
β-Blocker 0.003 0.333 (0.163; 0.683) 0.056 0.445 (0.194; 1.022)
PPI 0.548 0.809 (0.405; 1.615)
MELD score  < 0.001 1.123 (1.081; 1.167)  < 0.001 1.109 (1.066; 1.152)
Albumin 0.997 1.000 (0.938; 1.067)
CRP 0.042 1.004 (1.000; 1.007) 0.073
Leukocytes 0.067 1.017 (0.999; 1.036)
Sodium 0.688 0.991 (0.950; 1.034)
Platelets 0.046 0.966 (0.992; 1.000) 0.254

Laboratory values were assessed at time of the onset of nosocomial infection.

Significant values are in bold.

MELD model of end stage liver disease, CRP C-reactive protein, LTx Liver transplantation, PPI proton pump inhibitors, CI Confidence interval.

Differences in the most common sites of nosocomial infections

Overall, SBP (n = 136, 48%) was the most frequent nosocomial infection followed by UTI (n = 62, 22%). We documented only minor differences between male and female patients. SBP was the most frequent site of infection in men constituting to 53% (n = 96) of the infections. On the contrary, in only 34% (n = 40) of the infections in female patients a SBP was diagnosed (P = 0.048). In contrast, UTI was more common in females. In females 31% (n = 37) of the nosocomial infections could be attributed to the urinary tract whereas this was only the case in 14% (n = 25) of the infections in males (P < 0.001). Similar rates of pneumonia were detected among the infections in male and female patients (P = 0.758), while blood stream infections were more frequent in men (8% vs 3%, P = 0.154) (Fig. 2).

Figure 2.

Figure 2

Distribution of site of nosocomial infection. In some patients more than one nosocomial infection was present. SBP: spontaneous bacterial peritonitis; UTI: urinary tract infection.

Incidence and clinical course of as well as risk factor for nosocomial SBP in male vs. female patients

Although SBP was more frequent among the infection in males, the overall cumulative incidence of nosocomial SBP did not differ between male and female patients (P = 0.493) (Fig. 3). In the final multivariate competing risk model only presence of a peritoneal catheter (HR: 2.19; P < 0.001) was significantly linked to the development of nosocomial SBP (Table 3) in both female (HR: 3.46; P < 0.001) and male (HR: 1.85; P = 0.002) patients. In female patients the platelet count (HR: 1.003; P = 0.009) was also linked to SBP development.

Figure 3.

Figure 3

Incidence of nosocomial SBP. Death and LTx were treated as competing risk. LTx liver transplantation; SBP spontaneous bacterial peritonitis.

Table 3.

Multivariate competing risk analysis of incidence of nosocomial SBP.

Variable (all patients) P-value Hazard ratio (CI)
MELD score 0.088 1.0195 (0.9972, 1.0423)
Prior SBP 0.11 1.3445 (0.9337, 1.9359)
Platelets 0.074 1.0013 (0.9999, 1.0028)
Peritoneal catheter  < 0.001 2.1858 (1.5788, 3.0264)
Primary norfloxacin prophylaxis 0.076 0.5097 (0.2430, 1.0692)

Included parameters: sex, MELD score, diabetes, age, platelets, prior SBP, primary norfloxacin prophylaxis and peritoneal catheter.

SBP spontaneous bacterial peritonitis, MELD model of end stage liver disease, CI Confidence interval.

In 19 female patients (32%) with nosocomial SBP a pathogen was detected. In the majority of cases (84%) gram-positive bacteria were identified. Similarly, in 30 male patients with nosocomial SBP (27%) a pathogen was detected, which were also more frequently gram-positive bacteria (67%) (Suppl. Table 1).

The LTx-free survival after a nosocomial SBP did not differ between male and female patients (Table 6). Further, there was no difference between male and female patients in terms of the incidence of AKI and ACLF after nosocomial SBP (data not shown).

Table 6.

Uni- and multivariate Cox-regression of LTx-free survival after the onset of nosocomial SBP.

Variable Univariate Multivariate
P-value Hazard ratio (CI) P-value Hazard ratio (CI)
Sex (male) 0.696 0.862 (0.410; 1.812) 0.659
Age 0.682 1.007 (0.975; 1.039)
Diabetes 0.360 0.659 (0.269; 1.611)
Esophageal varices 0.735 0.870 (0.387; 1.954)
β-Blocker 0.010 0.247 (0.086; 0.711) 0.058 0.349 (0.117; 1.038)
PPI 0.847 1.110 (0.385; 3.199)
MELD score  < 0.001 1.131 (1.082; 1.183) 0.001 1.096 (1.041; 1.154)
Albumin 0.309 0.953 (0.869; 1.046)
CRP 0.001 1.006 (1.002; 1.009)  < 0.001 1.010 (1.005; 1.016)
Leukocytes 0.077 1.018 (0.998; 1.038)
Sodium 0.530 1.020 (0.960; 1.083)
Platelets 0.013 0.992 (0.986; 0.998) 0.080 0.994 (0.988; 1.001)
Protein ascites 0.502 0.736 (0.300; 1.802)
Nucleus containing cells 0.839 0.993 (0.932; 1.059)

Laboratory values were assessed at time of the onset of nosocomial SBP.

Significant values are in bold.

LTx liver transplantation, SBP spontaneous bacterial peritonitis, MELD model of end stage liver disease, CRP C-reactive protein, CI Confidence interval.

Incidence and clinical course of nosocomial UTI in male vs. female patients

Cumulative incidence of nosocomial UTI was significantly higher in female than in male patients (P < 0.001) (Fig. 4). Moreover, female sex was identified as an independent risk factor for the incidence of UTI in the multivariate competing risk analysis (HR: 2.16; P < 0.001). Other independent risk factors for UTI included use of a urinary catheter (HR: 3.94, P < 0.001) and a higher MELD score (HR: 1.04; P = 0.008) (Table 4). Of note, considering only male patients urinary catheter was detected as the only risk factor (HR: 5.4, P < 0.001).

Figure 4.

Figure 4

Incidence of nosocomial UTI. Death and LTx were treated as competing risk. LTx liver transplantation; UTI urinary tract infection.

Table 4.

Multivariate competing risk analysis of incidence of nosocomial UTI.

Variable (all patients) P-value Hazard ratio (CI)
Sex (female)  < 0.001 2.1576 (1.3828, 3.3667)
Urinary catheter  < 0.001 3.9354 (2.4975, 6.2011)
MELD score 0.008 1.0386 (1.0099, 1.0681)
Age 0.053 1.0199 (0.9999, 1.0403)

Included parameters: Age, sex, urinary catheter, MELD score, diabetes and platelets.

UTI urinary tract infection, MELD model of end stage liver disease, CI Confidence interval.

Overall, in 24 female patients with nosocomial UTI a pathogen was detected (48%). Gram-positive bacteria and gram-negative bacteria were detected in 62% and 54%, respectively. In 11 female patients more than one pathogen was present. However, this was mostly due to the presence of Candida species. Further, in 24 of the male patients a pathogen was detected (59%). Gram-positive bacteria were identified in 16 male patients (67%) while gram-negative bacteria were present in 10 men (41%) and in 6 male patients more than one pathogen was detected (Suppl. Table 1).

Of note, among those with nosocomial UTI, sex was not documented as relevant risk factor for mortality/LTx (Table 7).

Table 7.

Uni- and multivariate Cox-regression of LTx-free survival after the onset of nosocomial UTI.

Variable Univariate Multivariate
P-value Hazard ratio (CI) P-value Hazard ratio (CI)
Sex (male) 0.533 1.313 (0.557; 3.092) 0.769
Age 0.851 1.004 (0.964; 1.045)
Diabetes 0.560 1.349 (0.493; 3.693)
Esophageal varices 0.166 2.372 (0.699; 8.056)
β-Blocker 0.054 0.339 (0.133; 1.019)
PPI 0.893 1.089 (0.315; 3.764)
MELD score  < 0.001 1.146 (1.085; 1.211)  < 0.001 1.146 (1.085; 1.211)
Albumin 0.259 0.958 (0.889; 1.032)
CRP 0.605 1.002 (0.995; 1.009)
Leukocytes 0.058 1.060 (0.998; 1.127)
Sodium 0.519 0.978 (0.914; 1.046)
Platelets 0.223 0.996 (0.989; 1.002)

Laboratory values were assessed at time of the onset of nosocomial UTI.

Significant values are in bold.

LTx liver transplantation, UTI urinary tract infection, MELD model of end stage liver disease, CRP C-reactive protein, CI Confidence interval.

Discussion

There are significant differences in the etiology and the progression of liver disease between men and women5–7. Moreover, in those with end stage liver disease sex has been documented as a relevant factor with respect to the likelihood for transplantation and survival in some studies14,15. Nosocomial infections are a common and particularly severe complication at this stage that significantly alter the natural course of the disease36. Men and women differ in various parts including the distribution of immune cells10. Thus, we hypothesized that differences in the incidence and outcome of infections need to be considered that would partly explain the differences in the outcome of advanced liver cirrhosis that was documented between sexes in some studies. However, in our large well-defined cohort no major differences between male and female patients were identified.

There was a slightly, numerically lower incidence of nosocomial infections in male patients. However, this was not statistically significant after adjusting for the severity of liver disease and other relevant confounders. Moreover, the difference between males and females was mostly related to the higher incidence of UTI that was documented in female patients. The higher incidence of UTI is not surprising and well in line to other studies37–40. Of note, nosocomial UTI was not linked to a higher mortality compared to other infections. Thus, it seems unlikely that this results in a higher waiting list mortality that was described in prior studies14,16,17,41.

Of note, there was a trend towards a higher incidence of SBP in male patients. In line with our data O´Leary et al. reported a numerical higher incidence of SBP in men compared to women. However, this was not further investigated16. The main route of SBP is bacterial translocation from the intestinum42. Recent studies pointed out that the gut microbiome differs between men and women43,44, which may alter the likelihood for SBP as well as detectable bacteria. Indeed, there were some minor differences in the detected pathogens between male and female patients with SBP. However, the numbers were too small to draw any meaningful conclusion.

Infections are without a doubt one of the major hazards when managing female as well as male patients with end-stage liver disease. Early diagnosis, immediate treatment and in particular the development of prophylactic measures are key challenges to improve patients’ outcome. Therefore, it is important to define risk factors for infections in general as well as specific sites of infection in this cohort. We identified the presence of a peritoneal and urinary catheter as risk factor for the and development of nosocomial SBP and UTI, respectively. This was not different between male and female patients. Of note, in male patient urinary catheter was even the only independent risk factor for UTI. The high prevalence of UTIs in patients with urinary catheter is well in line with studies investigating the incidence of UTI in non-cirrhotic cohorts45. Temporary urinary catheter might be useful to document urinary output if required for patient management. The placement of a peritoneal catheter in hospitalized patients with ascites is not so common, so far. Nevertheless, repetitive paracentesis can be avoided46. However, our data emphasize that the indication for urinary catheter as well as peritoneal catheters should be critically evaluated and be removed as soon as possible47. This of particular importance in patients with decompensated cirrhosis who are particularly vulnerable for infections48,49.

The main limitation of our study is the retrospective single-center design. Therefore, some aspects of the management of patients might be center specific and the clinical diagnosis of infection may vary between the treating physicians. Moreover, the polymorphonuclear cell count in ascites was not available in our center at time of study inclusion. Therefore, in a few patients diagnosis of SBP might be a misclassification. However, the same criteria were applied in male and female patients. Further, a large number of patients was included in our study and our data provides some valuable information for future research questions. Moreover, it is to our best knowledge the first study that specifically addressed the impact of sex on the incidence and outcome of nosocomial infections among patients with decompensated liver cirrhosis.

To conclude, women developed only a numerical higher incidence of nosocomial infections, which are mostly due to a higher risk for UTI. Similar risk factors need to be considered for both sexes, which includes the use of temporary catheters. However, male and female do not differ with respect to the outcome of infections with respect to AKI, ACLF and LTx-free survival. Thus, a similar management seems appropriate.

Supplementary Information

Abbreviations

LTx-free survival

Liver transplant free survival

AKI

Acute kidney injury

ACLF

Acute on chronic liver failure

UTI

Urinary tract infection

SBP

Spontaneous bacterial peritonitis

HIV

Human Immunodeficiency Virus

GFR

Glomerular filtration rate

EASL

The European Association for the Study of the Liver

PPI

Proton pump inhibitors

CRP

C-reactive protein

AIC

Akaike’s information criterion

HR

Hazard Ratio

CI

Confidence interval

HE

Hepatic encephalopathy

HRS

Hepatorenal syndrome

TIPS

Transjugular intrahepatic portosystemic shunt

LTx

Liver transplantation

Author contributions

Data extraction and cleaning: M.G., T.L.T., N.S., A.R.K. Data analysis: M.G., T.L.T., B.M. Data interpretation: M.G., M.M., H.W., M.C., B.M. Manuscript writing: M.G., B.M. Critical manuscript review and editing: all authors. All authors read and approved the final manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL. MS and this study were supported by the ‘KlinStrucMed Programm – Promotionskolleg’ funded by the Else Kröner-Fresenius-Stiftung. BM was supported by the clinician scientist program of Hannover Medical School.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-022-07084-9.

References

  • 1.Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin. Pharmacokinet. 2009;48(3):143–157. doi: 10.2165/00003088-200948030-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Ayyar VS, DuBois DC, Nakamura T, Almon RR, Jusko WJ. Modeling corticosteroid pharmacokinetics and pharmacodynamics, part II: sex differences in methylprednisolone pharmacokinetics and corticosterone suppression. J. Pharmacol. Exp. Ther. 2019;370(2):327–336. doi: 10.1124/jpet.119.257527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Regitz-Zagrosek V, Kararigas G. Mechanistic pathways of sex differences in cardiovascular disease. Physiol. Rev. 2017;97(1):1–37. doi: 10.1152/physrev.00021.2015. [DOI] [PubMed] [Google Scholar]
  • 4.Pike CJ. Sex and the development of Alzheimer's disease. J. Neurosci. Res. 2017;95(1–2):671–680. doi: 10.1002/jnr.23827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Kaplan MM. Primary biliary cirrhosis. N. Engl. J. Med. 1996;335(21):1570–1580. doi: 10.1056/NEJM199611213352107. [DOI] [PubMed] [Google Scholar]
  • 6.Béland K, Lapierre P, Alvarez F. Influence of genes, sex, age and environment on the onset of autoimmune hepatitis. World J. Gastroenterol. WJG. 2009;15(9):1025. doi: 10.3748/wjg.15.1025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Fraga M, Fournier N, Safroneeva E, Pittet V, Godat S, Straumann A, et al. Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up. Eur. J. Gastroenterol. Hepatol. 2017;29(1):91–97. doi: 10.1097/MEG.0000000000000747. [DOI] [PubMed] [Google Scholar]
  • 8.Corrao G, Aricò S, Zambon A, Torchio P, Di Orio F. Female sex and the risk of liver cirrhosis. Collaborative Groups for the Study of Liver Diseases in Italy. Scand J. Gastroenterol. 1997;32(11):1174–80. doi: 10.3109/00365529709002999. [DOI] [PubMed] [Google Scholar]
  • 9.Yokoyama Y, Nimura Y, Nagino M, Bland KI, Chaudry IH. Current understanding of gender dimorphism in hepatic pathophysiology. J. Surg. Res. 2005;128(1):147–156. doi: 10.1016/j.jss.2005.04.017. [DOI] [PubMed] [Google Scholar]
  • 10.Durazzo M, Belci P, Collo A, Prandi V, Pistone E, Martorana M, et al. Gender specific medicine in liver diseases: a point of view. World J. Gastroenterol. 2014;20(9):2127–35. doi: 10.3748/wjg.v20.i9.2127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Stroffolini T, Esvan R, Biliotti E, Sagnelli E, Gaeta GB, Almasio PL. Gender differences in chronic HBsAg carriers in Italy: evidence for the independent role of male sex in severity of liver disease. J. Med. Virol. 2015;87(11):1899–1903. doi: 10.1002/jmv.24243. [DOI] [PubMed] [Google Scholar]
  • 12.Guy J, Peters MG. Liver disease in women: the influence of gender on epidemiology, natural history, and patient outcomes. Gastroenterol. Hepatol. (N Y). 2013;9(10):633–639. [PMC free article] [PubMed] [Google Scholar]
  • 13.Shimizu I. Impact of oestrogens on the progression of liver disease. Liver Int. 2003;23(1):63–69. doi: 10.1034/j.1600-0676.2003.00811.x. [DOI] [PubMed] [Google Scholar]
  • 14.Moylan CA, Brady CW, Johnson JL, Smith AD, Tuttle-Newhall JE, Muir AJ. Disparities in liver transplantation before and after introduction of the MELD score. JAMA. 2008;300(20):2371–8. doi: 10.1001/jama.2008.720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Myers RP, Shaheen AAM, Aspinall AI, Quinn RR, Burak KW. Gender, renal function, and outcomes on the liver transplant waiting list: assessment of revised MELD including estimated glomerular filtration rate. J. Hepatol. 2011;54(3):462–470. doi: 10.1016/j.jhep.2010.07.015. [DOI] [PubMed] [Google Scholar]
  • 16.O’Leary JG, Wong F, Reddy KR, Garcia-Tsao G, Kamath PS, Biggins SW, et al. Gender-specific differences in baseline, peak, and delta serum creatinine: the NACSELD experience. Dig. Dis. Sci. 2017;62(3):768–76. doi: 10.1007/s10620-016-4416-7. [DOI] [PubMed] [Google Scholar]
  • 17.Cholongitas E, Marelli L, Kerry A, Goodier DW, Nair D, Thomas M, et al. Female liver transplant recipients with the same GFR as male recipients have lower MELD scores–a systematic bias. Am. J. Transpl. 2007;7(3):685–692. doi: 10.1111/j.1600-6143.2007.01666.x. [DOI] [PubMed] [Google Scholar]
  • 18.Mariante-Neto G, Marroni CP, Fleck Junior AM, Marroni CA, Zanotelli ML, Cantisani G, et al. Impact of creatinine values on MELD scores in male and female candidates for liver transplantation. Ann. Hepatol. 2013;12(3):434–9. [PubMed] [Google Scholar]
  • 19.Umemura T, Joshita S, Shibata S, Sugiura A, Yamazaki T, Fujimori N, et al. Renal impairment is associated with increased risk of mortality in patients with cirrhosis: a retrospective cohort study. Medicine (Baltimore). 2019;98(6):e14475. doi: 10.1097/MD.0000000000014475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Dionigi E, Garcovich M, Borzio M, Leandro G, Majumdar A, Tsami A, et al. Bacterial infections change natural history of cirrhosis irrespective of liver disease severity. Am. J. Gastroenterol. 2017;112(4):588–96. doi: 10.1038/ajg.2017.19. [DOI] [PubMed] [Google Scholar]
  • 21.Arvaniti V, D'Amico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139(4):1246–1255. doi: 10.1053/j.gastro.2010.06.019. [DOI] [PubMed] [Google Scholar]
  • 22.Kimmann M, Tergast TL, Schultalbers M, Laser H, Gerbel S, Manns MP, et al. Sustained impact of nosocomial-acquired spontaneous bacterial peritonitis in different stages of decompensated liver cirrhosis. PloS One. 2019;14(8):1447. doi: 10.1371/journal.pone.0220666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Merli M, Lucidi C, Pentassuglio I, Giannelli V, Giusto M, Di Gregorio V, et al. Increased risk of cognitive impairment in cirrhotic patients with bacterial infections. J. Hepatol. 2013;59(2):243–250. doi: 10.1016/j.jhep.2013.03.012. [DOI] [PubMed] [Google Scholar]
  • 24.Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426–1429. doi: 10.1053/j.gastro.2013.02.042. [DOI] [PubMed] [Google Scholar]
  • 25.Maiwall R, Sarin SK, Kumar S, Jain P, Kumar G, Bhadoria AS, et al. Development of predisposition, injury, response, organ failure model for predicting acute kidney injury in acute on chronic liver failure. Liver Int. 2017;37(10):1497–507. doi: 10.1111/liv.13443. [DOI] [PubMed] [Google Scholar]
  • 26.Kim JJ, Tsukamoto MM, Mathur AK, Ghomri YM, Hou LA, Sheibani S, et al. Delayed paracentesis is associated with increased in-hospital mortality in patients with spontaneous bacterial peritonitis. Am. J. Gastroenterol. 2014;109(9):1436–1442. doi: 10.1038/ajg.2014.212. [DOI] [PubMed] [Google Scholar]
  • 27.Arroyo V, Jalan R. Acute-on-chronic liver failure: definition, diagnosis, and clinical characteristics. Semin. Liver Dis. 2016;36(2):109–16. doi: 10.1055/s-0036-1583202. [DOI] [PubMed] [Google Scholar]
  • 28.Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, et al. Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology. 2015;62(1):243–252. doi: 10.1002/hep.27849. [DOI] [PubMed] [Google Scholar]
  • 29.European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J. Hepatol. 69(2), 406–460 (2018). [DOI] [PubMed]
  • 30.Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. Gut. 2015;64(4):531–537. doi: 10.1136/gutjnl-2014-308874. [DOI] [PubMed] [Google Scholar]
  • 31.Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 1999;94(446):496–509. [Google Scholar]
  • 32.Stepwise Covariate Selection for the Fine & Gray Competing Risks.
  • 33.Regression Model [Internet].; 2015 [updated Feb 23,; cited 19.03.2019]. Available from: https://cran.r-project.org/web/packages/crrstep/crrstep.pdf.
  • 34.Kuk D, Varadhan R. Model selection in competing risks regression. Stat. Med. 2013;32(18):3077–3088. doi: 10.1002/sim.5762. [DOI] [PubMed] [Google Scholar]
  • 35.crrstep.output: Transform the result of ccrstep [Internet].; 2017 [updated Sep 23,; cited 19.03.2019]. Available from: https://rdrr.io/github/SophiaJia/Jsurvformat/man/crrstep.output.html#heading-1.
  • 36.Package 'cmprsk' [Internet]. [cited 02.09.2019]. Available from: https://cran.r-project.org/web/packages/cmprsk/cmprsk.pdf.
  • 37.Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Brujats A, Calleja JL, et al. Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. J. Hepatol. 2021;5:7189. doi: 10.1016/j.jhep.2021.04.022. [DOI] [PubMed] [Google Scholar]
  • 38.Reuken PA, Stallmach A, Bruns T. Mortality after urinary tract infections in patients with advanced cirrhosis-relevance of acute kidney injury and comorbidities. Liver Int. 2013;33(2):220–230. doi: 10.1111/liv.12029. [DOI] [PubMed] [Google Scholar]
  • 39.Fasolato S, Angeli P, Dallagnese L, Maresio G, Zola E, Mazza E, et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology. 2007;45(1):223–229. doi: 10.1002/hep.21443. [DOI] [PubMed] [Google Scholar]
  • 40.Rabinovitz M, Prieto M, Gavaler JS, Van Thiel DH. Bacteriuria in patients with cirrhosis. J. Hepatol. 1992;16(1–2):73–76. doi: 10.1016/s0168-8278(05)80097-2. [DOI] [PubMed] [Google Scholar]
  • 41.Cadranel JF, Denis J, Pauwels A, Barbare JC, Eugène C, di Martino V, et al. Prevalence and risk factors of bacteriuria in cirrhotic patients: a prospective case-control multicenter study in 244 patients. J. Hepatol. 1999;31(3):464–468. doi: 10.1016/s0168-8278(99)80038-5. [DOI] [PubMed] [Google Scholar]
  • 42.Lai JC, Terrault NA, Vittinghoff E, Biggins SW. Height contributes to the gender difference in wait-list mortality under the MELD-based liver allocation system. Am. J. Transplant. 2010;10(12):2658–2664. doi: 10.1111/j.1600-6143.2010.03326.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Ramachandran A, Balasubramanian KA. Intestinal dysfunction in liver cirrhosis: Its role in spontaneous bacterial peritonitis. J. Gastroenterol. Hepatol. 2001;16(6):607–612. doi: 10.1046/j.1440-1746.2001.02444.x. [DOI] [PubMed] [Google Scholar]
  • 44.Min Y, Ma X, Sankaran K, Ru Y, Chen L, Baiocchi M, et al. Sex-specific association between gut microbiome and fat distribution. Nat. Commun. 2019;10(1):1–9. doi: 10.1038/s41467-019-10440-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Takagi T, Naito Y, Inoue R, Kashiwagi S, Uchiyama K, Mizushima K, et al. Differences in gut microbiota associated with age, sex, and stool consistency in healthy Japanese subjects. J. Gastroenterol. 2019;54(1):53–63. doi: 10.1007/s00535-018-1488-5. [DOI] [PubMed] [Google Scholar]
  • 46.Geerlings SE. Clinical presentations and epidemiology of urinary tract infections. Urin. Tract Infect. Mol. Pathog. Clin. Manag. 2017;71:27–40. [Google Scholar]
  • 47.Stratmann K, Fitting D, Zeuzem S, Bojunga J, Trebicka J, Friedrich-Rust M, et al. Establishing an indwelling peritoneal catheter as a standard procedure for hospitalized patients with ascites: Retrospective data on feasibility, effectiveness and safety. United Eur. Gastroenterol. J. 2019;7(5):673–681. doi: 10.1177/2050640619842442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin. Infect. Dis. 2010;50(5):625–663. doi: 10.1086/650482. [DOI] [PubMed] [Google Scholar]
  • 49.Schultalbers M, Tergast TL, Simon N, Kabbani A, Kimmann M, Zu Siederdissen CH, et al. Frequency, characteristics and impact of multiple consecutive nosocomial infections in patients with decompensated liver cirrhosis and ascites. United Eur. Gastroenterol. J. 2020;8(5):567–576. doi: 10.1177/2050640620913732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Fernández J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;35(1):140–148. doi: 10.1053/jhep.2002.30082. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials


Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES